Ignite Creation Date:
2024-07-17 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06465446
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-24
First Post:
2024-06-13
Brief Title:
A Study of IMM01 Plus Tiselizumab Versus Physicians Choice Chemotherapy in PDL1-refractory Classical Hodgkin Lymphoma
Sponsor:
ImmuneOnco Biopharmaceuticals Shanghai Inc
Organization:
ImmuneOnco Biopharmaceuticals Shanghai Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-06
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-06
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-07
Completion Date Type:
ESTIMATED
First Submit Date:
2024-06-13
First Submit QC Date:
None
Study First Post Date:
2024-06-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-06-19
Last Update Post Date:
2024-06-24
Last Update Post Date Type:
ACTUAL